Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-13043 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
filingDate |
2019-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0304a991e91ffa605ac509b7e9e50459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce18ce0abb177d59799b8c1d45ccf554 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2b655cb5f2f86ea40aeba4a111592f3 |
publicationDate |
2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019204662-A1 |
titleOfInvention |
Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
abstract |
Embodiments of the disclosure include methods and compositions related to improvements of T cell therapy. In particular embodiments, CD8+ T cell therapy is enhanced upon expression of transgenic Ε08αβ co-receptor in the CD8+ T cells. In certain embodiments, CD4+ T cells are rendered to have cytotoxic cell function for adoptive transfer upon expression of transgenic Ε08αβ co-receptor in the CD4+ T cells. In specific embodiments, TCR- expressing and Ε08αβ co-receptor-expressing CD4+ and CD8+ T cells are utilized in adoptive transfer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020376031-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020243134-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020049496-A1 |
priorityDate |
2018-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |